Novel Potassium Channel Opener Safe, Effective for Adults With Focal Epilepsy
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 11, 2023 -- XEN1101 appears safe and effective for the treatment of focal-onset seizures (FOSs), according to results of a phase 2b study published online Oct. 9 in JAMA Neurology.
Jacqueline A. French, M.D., from the New York University Comprehensive Epilepsy Center in New York City, and colleagues evaluated the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, for the treatment of FOS. The analysis included 285 patients who were randomly assigned (2:1:1:2) to receive XEN1101 25, 20, or 10 mg, or placebo with food once daily for eight weeks.
The researchers reported that treatment with XEN1101 was associated with seizure reduction in a robust dose-response manner. From baseline, the median percent reduction in monthly FOS frequency was 52.8 percent for 25 mg, 46.4 percent for 20 mg, and 33.2 percent for 10 mg. Treatment-emergent adverse events were similar to those of commonly prescribed antiseizure medications.
"The results of this study support the further clinical development of XEN1101 for the treatment of FOSs," the authors write. "The findings of this study suggest that XEN1101 has the potential to address the unmet need for a treatment with a novel mechanism of action for patients."
Several authors disclosed ties to pharmaceutical companies, including Xenon Pharmaceuticals, which is developing XEN1101.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Angiotensin Receptor Blocker Use Linked to Lower Incidence of Epilepsy
FRIDAY, June 21, 2024 -- For patients with hypertension, angiotensin receptor blockers (ARBs) are associated with a reduced incidence of epilepsy compared with other...
Epilepsy Surgery for Neuroglial Tumors Shows Good Long-Term Outcomes
MONDAY, June 17, 2024 -- Patients with neuroglial tumors are ideal epilepsy surgical candidates, with good long-term outcomes observed, according to a study published online May...
In Utero Exposure to Antiseizure Meds Does Not Affect Child Creativity
WEDNESDAY, May 29, 2024 -- There are no differences in creative thinking at age 4.5 years for children of women with epilepsy (WWE) and children of healthy women (HW), but fetal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.